Besifloxacin

證據等級: L5

預測適應症: 8 個

Besifloxacin: From Bacterial Conjunctivitis to Bronchitis

One-Sentence Summary

Besifloxacin (Besivance®) is a fourth-generation fluoroquinolone antibiotic formulated exclusively as an ophthalmic suspension for the treatment of bacterial conjunctivitis. The TxGNN model assigns its highest prediction score to Bronchitis (99.84%), but this likely reflects a class-effect over-extrapolation from the broader fluoroquinolone drug class — besifloxacin’s systemic bioavailability after topical ocular administration is near-zero (<1 ng/mL plasma concentration), rendering the respiratory indication pharmacologically implausible in its current formulation. There are no clinical trials and no publications directly supporting this predicted new indication.

Quick Overview

Item	Content
Original Indication	Bacterial Conjunctivitis (ophthalmic topical use)
Predicted New Indication	Bronchitis
TxGNN Prediction Score	99.84%
Evidence Level	L5
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacology, Besifloxacin belongs to the fluoroquinolone antibiotic class, acting by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV — enzymes essential for bacterial DNA replication, transcription, and repair. Its antibacterial spectrum covers key ocular pathogens (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Haemophilus influenzae), which overlap substantially with common bronchitis-causing bacteria.

The TxGNN score of 99.84% for bronchitis is almost certainly driven by class-level knowledge graph linkages rather than drug-specific signals. Systemic fluoroquinolones such as levofloxacin and moxifloxacin carry approved respiratory indications — including community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis — and these drug-disease edges in the knowledge graph are likely being inherited by besifloxacin. This is a recognised limitation of graph-based prediction models when a drug belongs to a well-characterised pharmacological class.

There is, however, a critical and deliberate pharmacological barrier: besifloxacin was engineered specifically to minimise systemic absorption. Phase 1 pharmacokinetic data (NCT00407589) confirm that plasma concentrations after topical ocular dosing remain well below 1 ng/mL — many orders of magnitude below the minimum inhibitory concentrations required to treat lower respiratory tract pathogens. No systemic oral or parenteral formulation of besifloxacin exists. The prediction does not represent a feasible repurposing opportunity under the drug’s current formulation strategy.

Clinical Trial Evidence

Currently no related clinical trials registered for Besifloxacin in Bronchitis.

Context note: Six clinical trials were retrieved when querying Besifloxacin against the adjacent predicted indication “post-bacterial disorder” (rank 3), but all six trials involve the drug’s existing ophthalmic indications (bacterial conjunctivitis treatment and cataract surgery prophylaxis). They provide no evidence of new indication development and are listed here for transparency only.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01175590	Phase 3	Completed	518	Safety of Besivance 0.6% vs. vehicle TID × 7 days in bacterial conjunctivitis — established local ocular safety profile
NCT01740388	Phase 3	Terminated	136	Efficacy of Besifloxacin BID × 3 days vs. vehicle in bacterial conjunctivitis — terminated early, reducing evidence quality
NCT01478256	Phase 4	Completed	30	Besifloxacin vs. erythromycin ointment for acute blepharitis — small post-marketing comparator study
NCT01296542	Phase 4	Completed	60	Besivance vs. VIGAMOX for pre-operative conjunctival decontamination before cataract surgery
NCT00407589	Phase 1	Completed	24	Systemic pharmacokinetics after single/multiple topical instillations — confirmed near-zero systemic exposure (<1 ng/mL), key finding limiting all systemic repurposing hypotheses
NCT04542759	Phase 1	Completed	60	Reduction of ocular surface microbiota prior to cataract surgery — microbiological endpoints only, no new indication signal

Literature Evidence

Currently no related literature available for Besifloxacin in Bronchitis.

India Market Information

Besifloxacin is currently not marketed in India. No product authorisations or registration numbers are on record.

Safety Considerations

Please refer to the package insert for safety information.

Package insert data (TFDA/CDSCO warnings, contraindications) were not available at the time of this analysis. Retrieval from the regulatory agency’s official website is recommended before any prescribing or protocol development.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite an exceptionally high TxGNN prediction score (99.84%), the bronchitis indication is pharmacologically implausible for besifloxacin in its current ophthalmic formulation. The signal is a class-effect artefact derived from the broader fluoroquinolone drug class — not a drug-specific repurposing opportunity. No clinical trials, literature, or preclinical data support this new use, and the drug’s deliberate design for minimal systemic absorption constitutes a fundamental formulation barrier.

To proceed, the following is needed:

Formulation feasibility assessment: Determine whether a systemic oral or IV formulation of besifloxacin has ever been developed or is pharmacologically viable; without this, no systemic indication can be pursued
PK/PD modelling: Establish theoretical plasma concentrations achievable under a hypothetical systemic formulation and compare against MIC breakpoints for S. pneumoniae, H. influenzae, and M. pneumoniae
Mechanism of action documentation: Retrieve full MOA data from DrugBank (DB06771) to enable mechanistic link analysis
Safety data retrieval: Download and parse the TFDA/CDSCO package insert PDF to extract warnings, contraindications, and special population data
Exploratory hypothesis — Otitis Externa: Among all 8 TxGNN predictions reviewed, otitis externa (rank 8, score 99.03%) is the only indication with a mechanistic rationale consistent with besifloxacin’s topical route. Other fluoroquinolone ear drop formulations (ciprofloxacin/dexamethasone, ofloxacin) target the same pathogens (P. aeruginosa, S. aureus) via the same local delivery mechanism. This hypothesis warrants a dedicated preclinical feasibility study before any clinical development decision

⚠️ This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.